€4.98
0.40% day before yesterday
Paris, Oct 03, 05:35 pm CET
ISIN
FR0004056851
Symbol
VLA

Valneva Stock price

€4.98
+1.15 29.99% 1M
+1.80 56.87% 6M
+2.81 130.16% YTD
+2.46 97.46% 1Y
-0.34 6.40% 3Y
-1.78 26.39% 5Y
+1.76 54.53% 10Y
-5.98 54.60% 20Y
Paris, Closing price Fri, Oct 03 2025
-0.02 0.40%
ISIN
FR0004056851
Symbol
VLA
Industry

Key metrics

Basic
Market capitalization
€858.0m
Enterprise Value
€893.6m
Net debt
€35.6m
Cash
€161.3m
Shares outstanding
162.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.9 | 4.4
EV/Sales
3.1 | 4.6
EV/FCF
negative
P/B
4.6
Financial Health
Equity Ratio
36.3%
Return on Equity
-6.8%
ROCE
-19.8%
ROIC
-25.5%
Debt/Equity
1.1
Financials (TTM | estimate)
Revenue
€291.4m | €194.6m
EBITDA
€-38.2m | €-48.4m
EBIT
€-68.6m | €-63.9m
Net Income
€-85.5m | €-77.4m
Free Cash Flow
€-26.9m
Growth (TTM | estimate)
Revenue
31.5% | 14.8%
EBITDA
-108.4% | -328.6%
EBIT
-51.0% | -563.4%
Net Income
-1,007.6% | -531.6%
Free Cash Flow
87.5%
Margin (TTM | estimate)
Gross
48.9%
EBITDA
-13.1% | -24.9%
EBIT
-23.5%
Net
-29.4% | -39.8%
Free Cash Flow
-9.2%
More
EPS
€-0.5
FCF per Share
€-0.2
Short interest
-
Employees
713
Rev per Employee
€240.0k
Show more

Is Valneva a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Valneva Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Valneva forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Valneva forecast:

Buy
80%
Hold
20%

Financial data from Valneva

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
291 291
31% 31%
100%
- Direct Costs 149 149
10% 10%
51%
143 143
66% 66%
49%
- Selling and Administrative Expenses 130 130
13% 13%
45%
- Research and Development Expense 111 111
19% 19%
38%
-38 -38
108% 108%
-13%
- Depreciation and Amortization 30 30
12% 12%
10%
EBIT (Operating Income) EBIT -69 -69
51% 51%
-24%
Net Profit -86 -86
1,008% 1,008%
-29%

In millions EUR.

Don't miss a Thing! We will send you all news about Valneva directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Valneva Stock News

AD HOC NEWS
about one month ago
Eine negative Entscheidung der US-Gesundheitsbehörde FDA zu einem Impfstoff von Valneva FR0004056851 hat die Papiere der Franzosen am Montag schwer belastet.
AD HOC NEWS
about 2 months ago
Robuste Geschäftszahlen zum ersten Halbjahr haben die Aktien von Valneva FR0004056851 am Dienstag angetrieben.

Company Profile

Valneva SE is a biotech company. The firm engages in the development, production and marketing of vaccine and preventive medicine. It operates through the following segments: Commercialized Vaccines, Technologies and Services and Vaccine Candidates. The Commercialized Vaccines segment includes currently marketed vaccines of the group such as JEV and DUKORAL. The Technologies and Services segment regroups services and inventions in commercialization stage. The Vaccine Candidates segment consists of proprietary research and development programs aiming to generate new approvable products. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Head office France
CEO Thomas Lingelbach
Employees 713
Founded 1999
Website valneva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today